Abstract Library

#3572 Capecitabine and temozolomide in advanced neuroendocrine neoplasms – A single center experience

Introduction: Neuroendocrine neoplasms (NENs) are heterogeneous malignancies, with a great variability in clinical behaviour and prognosis. Capecitabine and temozolomide combination (CAPTEM) has shown positive results in these patients, with a good safety profile.

Conference:

Presenting Author:

Authors: Monteiro J, Caetano A, Pires M, Costa C, Elvas A,

Keywords: neuroendocrine neoplasm, neuroendocrine tumor, treatment, capecitabine, temozolomide, capecitabine and temozolomide, CAPTEM,

#3570 Metastatic middle ear neuroendocrine tumor treated with Somatostatin analogues and PRRT – A case report

Introduction: Neuroendocrine adenomas of the middle ear (NEAME) are rare tumors. They have mostly indolent biological behaviour, however, reports of an aggressive course and metastasis have been described.

Conference:

Presenting Author: Gomes Martins R

Authors: Elvas A, Magalhães J, Monteiro J, Barros J, Rei L,

Keywords: Neuroendocrine adenomas of the middle ear, somatostatin analogues, peptide receptor radionuclide therapy,

#3565 Grade 3 neuroendocrine neoplasms – Real life experience and prognostic biomarkers

Introduction: Grade 3 neuroendocrine neoplasms (G3 NEN) are a heterogeneous group, including well differentiated tumors (NET) and poorly differentiated carcinomas (NEC), whose identification can be challenging. Accessible prognostic tools are needed to individualize treatment. Data suggests neutrophil/lymphocyte ratios (NLR) and systemic inflammatory index (SII) have prognostic value in NEN.

Conference:

Presenting Author: Rebordão Pires M

Authors: Rebordão Pires M, Monteiro J, Amorim Costa C, Caetano A, Elvas A,

Keywords: Grade 3 neuroendocrine neoplasm, NEC, NET, Neutrophil to lymphocyte ratio, Systemic Inflammatory Index, Ki67, Prognostic biomarker,

#3564 Prevalence of other malignant cancers in patients with neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NNE) are a heterogeneous group, arising from different anatomical locations. Studies showed a higher prevalence of other malignancies associated with NNE when compared to other types of cancer.

Conference:

Presenting Author: Amorim Costa C

Authors: Amorim Costa C, Peixoto M, Rebordão Pires M, Cruz Monteiro J, Elvas A,

Keywords: Neuroendocrine neoplasm, solid malignancies, hematological malignancies, screening,

#3413 Visceral obesity at diagnosis is associated with well-differentiated neuroendocrine neoplasia lower progression free survival

Introduction: The association of well-differentiated gastroenteropancreatic neuroendocrine neoplasia (WD GEP-NEN) with metabolic syndrome (MetS), abdominal obesity, and fasting glucose abnormalities was recently described. Although the role of the intrinsic clinical, pathological, and molecular factors on GEP-NEN prognosis has been extensively studied, the association of adverse outcomes with obesity and metabolic risk factors was not identified so far.

Conference:

Presenting Author: Santos A

Authors: Santos A, Rodrigues J, Henrique R, Cardoso M, Monteiro M,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, metabolic syndrome, visceral obesity, overall survival, progression free survival,